Xinyang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinyang Li has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Danyang Li
School of Basic Medicine, Beijing Health Vocational College, Beijing 101109, China
1 shared publication - Minglian Wang
College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China
1 shared publication - Yuanfei Liu
College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China
1 shared publication
Latest Publications
- Open Access
Small Extracellular Vesicles of Diverse Cellular Origins: Biological Characteristics and Prospective Applications
Small extracellular vesicles (sEVs), commonly referred to as exosomes, are nanoscale vesicles that mediate intercellular communication and represent promising biotechnological platforms for disease diagnosis, therapeutic intervention, and drug delivery. sEVs derived from plants, mesenchymal stem cells, tumor cells, and immune cells display pronounced source-dependent heterogeneity shaped by parental cell lineage, differentiation status, and the local microenvironment. Such heterogeneity influences not only their biological properties, including physicochemical characteristics, molecular cargo profiles, and immunomodulatory functions, but also their manufacturing characteristics, in vivo tropism, and translational potential as biotherapeutics. Nevertheless, a comprehensive evaluation framework from a medical biotechnology perspective remains insufficiently established. In this review, the core biological features of multi-source sEVs are first outlined to establish a foundation for subsequent analysis. We then examine their biomedical applications and discuss biotechnological bottlenecks, including isolation and purification workflows, quality-control metrics, batch-to-batch variability, scalable biomanufacturing, and biosafety assessment. Particular attention is also given to the incompletely characterized regulatory networks of immune-cell-derived sEVs. Furthermore, we discuss how multi-omics profiling, standardized production protocols, and precision-engineering strategies may facilitate the functional optimization of source-specific sEVs. Collectively, this review provides an integrated medical biotechnology framework for evaluating multi-source sEVs and highlights practical considerations for accelerating the bench-to-bedside translation of sEV-based biotherapeutics.
Open AccessSmall Extracellular Vesicles of Diverse Cellular Origins: Biological Characteristics and Prospective Applications
Small extracellular vesicles (sEVs), commonly referred to as exosomes, are nanoscale vesicles that mediate intercellular communication and represent promising biotechnological platforms for disease diagnosis, therapeutic intervention, and drug delivery. sEVs derived from plants, mesenchymal stem cells, tumor cells, and immune cells display pronounced source-dependent heterogeneity shaped by parental cell lineage, differentiation status, and the local microenvironment. Such heterogeneity influences not only their biological properties, including physicochemical characteristics, molecular cargo profiles, and immunomodulatory functions, but also their manufacturing characteristics, in vivo tropism, and translational potential as biotherapeutics. Nevertheless, a comprehensive evaluation framework from a medical biotechnology perspective remains insufficiently established. In this review, the core biological features of multi-source sEVs are first outlined to establish a foundation for subsequent analysis. We then examine their biomedical applications and discuss biotechnological bottlenecks, including isolation and purification workflows, quality-control metrics, batch-to-batch variability, scalable biomanufacturing, and biosafety assessment. Particular attention is also given to the incompletely characterized regulatory networks of immune-cell-derived sEVs. Furthermore, we discuss how multi-omics profiling, standardized production protocols, and precision-engineering strategies may facilitate the functional optimization of source-specific sEVs. Collectively, this review provides an integrated medical biotechnology framework for evaluating multi-source sEVs and highlights practical considerations for accelerating the bench-to-bedside translation of sEV-based biotherapeutics.